WinstonWınston
Back
Deccan Health Care logo

Deccan Health Care

DECCAN.BO
44
Medical - Pharmaceuticals · Healthcare
Price
₹13.48
+0.60 (+4.66%)
Market Cap
₹333.6M
Exchange
Bombay Stock Exchange
Winston Score
44
Winston is serious
Mixed quality — meaningful strengths and weaknesses.
Data as of Aug 13, 2026 · filings through Mar 31, 2026
How the score breaks down
Quality
Weak
Growth
Good
Cash Flow
Weak
Stability
Exceptional
Valuation
Good

Share count rising — dilution

+56.7% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 15.7M (2022) → 24.6M (2026)

Winston Score History

The full picture

Deccan Health Care Ltd is an Indian pharmaceutical company that makes and sells a range of healthcare products, including nutritional supplements, vitamins, and specialty medicines. Its customers include hospitals, pharmacies, and individual consumers across India. The company operates in the broader Indian pharmaceuticals and nutraceuticals market, which has been growing steadily as more people focus on preventive health.

The company earns money primarily by manufacturing and selling its products to distributors and retailers, who then sell them to end customers. Deccan Health Care operates mainly within India, and with a market cap of roughly $0.3 billion, it is a small player in a highly competitive industry dominated by much larger domestic and multinational pharmaceutical companies. Its thin operating margin of around 4.4% and low return on invested capital highlight the key risk: the company must improve profitability and scale to stay competitive as larger rivals with stronger distribution networks and bigger research budgets continue to expand in the same market.

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+1.1% YoY

YoY Growth Rate

Slow revenue growth

EPS Growth

+133.7% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$0/ year

0.0% of revenue

Below sector average (18%)

Research and development spending

Insider Activity

80.8%ownership

Insiders own a meaningful stake in the company

Cash Position

Cash flow positive

$25M cash & investments

Company generates more cash than it spends — no dilution risk from fundraising

Growth context

Deccan Health Care is growing revenue at 1% year-over-year. The Winston Score measures business quality today — these growth metrics show what could matter tomorrow.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin
33.2%
Modest — 33.2% gross margin
Operating Margin
2.4%
Thin — 2.4% operating margin
ROCE
0.4%
Weak — 0.4% return on capital

ROIC between 0% and 5%. They earn a few cents back per dollar invested in the business.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY
+11.9%
Steady sales growth (+11.9% YoY)
EPS YoY
+79.0%
Earnings growing fast (+79.0% YoY)

Earnings growing 25%+ a year. The compounder zone.

EPS Consistency
3/8 quarters
Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion
0%
Weak — only 0% of profit becomes cash
FCF Margin
0.0%
Thin free cash flow (0.0%)

FCF margin between 0% and 10%. Some cash from sales, but not a lot.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity
0.04
Conservative — low debt load (0.04)
Interest Cover
9.89x
Comfortably covers interest (9.9x)

Interest coverage above 8. Profits cover interest many times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)
13.2x
Attractive valuation — P/E 13.2

P/E in the normal range. Price is roughly $15 for every $1 of yearly profit.

P/E vs Forward
N/A
not available
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial